insider sale

Liquidia's chairman sold $2.5M in stock but retained 2M+ shares. The 3% stake reduction reflects liquidity management, not lost confidence, as the company surges 159.5% and achieves profitability.

Maze Therapeutics CMO Harold Bernstein sold 15,000 shares (~$442K) via pre-planned trading arrangement. Retains 237K options amid clinical-stage biotech challenges.

Immunome's Chief Scientific Officer trimmed his stake by 30%, but the real catalyst is varegacestat's planned Q2 2026 FDA submission following positive Phase 3 trial results.

Ardelyx CEO sells $243K in shares via routine trading plan as company improves operationally; analysts see 170% upside potential.

AAR Corp.'s senior VP sold $705K in shares, but routine option exercise. Strong Q3 results drive stock near 52-week highs.

Agios insider Krishnan sells $82K in shares via routine RSU tax-withholding event. Retains 16,200 unvested RSUs and recent equity grants signal confidence amid PYRUKYND's 86% revenue growth.

Healthcare Services Group executive sells $54K in shares following 107% one-year gain. Company reports strong 2025 results and authorizes new $75M buyback.

Collegium's General Counsel sells modest stake as company bets $650M acquiring AZSTARYS to accelerate ADHD strategy shift, with Jornay PM showing 48% growth.

Sionna CLO liquidated 10,250 shares for $347k via pre-scheduled plan while retaining 50,935 options. Dual clinical trials expected mid-2026 with $310.3M cash runway through 2028.

Adaptive Biotechnologies' president sold $1.21M in shares via pre-planned transaction, yet retains substantial holdings. Stock up 51% annually as core MRD business surges.

Gulfport Energy's chief legal officer has sold off 91% of his stake over two years, most recently $418K in shares, while taking on interim chairman duties.

Liquidia's Chief Commercial Officer sold 80,000 shares worth $2.8M through pre-arranged plan while retaining substantial holdings as flagship product Yutrepia drives record quarterly profits.

Xenon Pharmaceuticals' CMO sold $78K in shares via routine vesting, as stock surges 55% following positive Phase 3 trial results and $750M capital raise.

Strategic Education's General Counsel sold 2,982 shares for $238,000 on March 18, maintaining her $4.47M position and signaling continued confidence in the company.

GigaCloud Technology's CTO sold $4.3M in shares, retaining majority stake. Stock up 165% annually with strong Q4 results, but valuation suggests selling over buying.

Adaptive Biotechnologies COO Julie Rubinstein sold 179,703 shares for $2.37M via pre-arranged tax plan as company posts strong 55% revenue growth.

Apogee Therapeutics CEO sells $1.5M in shares via pre-planned program amid stock's 100% surge, but bullish clinical data and $350M capitalization warrant investor focus.

AXT CEO Morris Young sells $1.4M in stock after 2,758% rally, retaining 2.3M shares amid surging AI data center demand.

Palvella COO sells ~$508K in shares via pre-planned trading arrangement amid 340% annual surge, driven by strong Phase 3 QTORIN rapamycin data and upcoming NDA submission.

The RealReal's CFO sold 51,585 shares ($479K) via automatic tax withholding, yet stock surged 46% annually on 15% revenue growth and margin expansion.